Their mission is to create a future where cognitive and mental health issues are identified at the earliest stages, enabling more effective treatments, reducing healthcare burdens, and improving overall wellbeing. By seamlessly integrating AI-driven diagnostic tools into healthcare systems, LANGaware empowers healthcare professionals with valuable insights for personalized care, driving early intervention and destigmatizing mental health challenges. Mr. Vounatsos, former CEO and Board Director of Biogen, a global leader in biotechnology, has recently joined LANGaware’s advisory board. His decades of experience mark a significant milestone for LANGaware, further strengthening the company’s overall impact.

LANGaware successfully raised $2 million in a Seed round led by Eleven Ventures, a leading early-stage venture capital firm in Southeast Europe. Strategic investors from the healthcare industry, alongside existing investor Metavallon VC also participated in the round. This funding will be used to enhance their technology and product, boosting their AI capabilities and expanding the company’s business development team. 

What problem is LANGAware solving? The company is addressing the challenge of early detection and monitoring of cognitive and behavioral health conditions, aiming to improve treatment outcomes by diagnosing these conditions at their earliest stages.

What’s innovative about LANGAware? The company uses AI-driven speech and voice biomarkers to detect cognitive and mental health diseases early, providing a clinically validated solution that integrates seamlessly into healthcare systems.

Who can use LANGAware?Healthcare professionals, hospitals, and clinics can use the company's AI diagnostic tools to gain insights into cognitive and mental health disorders for personalized patient care.